Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)

Journal of the American Medical Association

Volumn 288, Issue 23, 2002, Pages 2981-2997

  Furberg, Curt D ^c   Wright Jr , Jackson T ^a   Davis, Barry R ^b   Cutler, Jeffrey A ^c   Alderman, Michael ^c   Black, Henry ^c   Cushman, William ^c   Grimm, Richard ^c   Haywood, L Julian ^c   Leenen, Frans ^c   Oparil, Suzanne ^c   Probstfield, Jeffrey ^c   Whelton, Paul ^c   Nwachuku, Chuke ^c   Gordon, David ^c   Proschan, Michael ^c   Einhom, Paula ^c   Ford, Charles E ^c   Piller, Linda B ^c   Dunn, I Kay ^c   Goff, David ^c   Pressel, Sara ^c   Bettencourt, Judy ^c   DeLeon, Barbara ^c   Simpson, Lara M ^c   Blanton, Joe ^c   Geraci, Therese ^c   Walsh, Sandra M ^c   Nelson, Christine ^c   Rahman, Mahboob ^c   Juratovac, Anne ^c   Pospisil, Robert ^c   Carroll, Lillian ^c   Sullivan, Sheila ^c   Russo, Jeanne ^c   Barone, Gail ^c   Christian, Rudy ^c   Feldman, Sharon ^c   Lucente, Tracy ^c   Calhoun, David ^c   Jenkins, Kim ^c   McDowell, Peggy ^c   Johnson, Janice ^c   Kingry, Connie ^c   Alzate, Juan ^c   Margolis, Karen L ^c   Holland Klemme, Leslie Ann ^c   Jaeger, Brenda ^c   Williamson, Jeffrey ^c   Louis, Gail ^c   Ragusa, Pamela ^c   Williard, Angela ^c   Ferguson, R L Sue ^c   Tanner, Joanna ^c   Eckfeldt, John ^c   Crow, Richard ^c   Pelosi, John ^c   more..

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANTILIPEMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; LISINOPRIL; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; TREATMENT OUTCOME;

AGED; AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; CHLORTHALIDONE; DIURETICS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; LISINOPRIL; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TREATMENT OUTCOME;

EID: 0344373794     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.288.23.2981     Document Type: Article

References (55)

1. American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 2001.
2. Cutler JA, MacMahon SW, Furberg CD. Controlled clinical trials of drug treatment for hypertension: A review. Hypertension. 1989;13:136-144.
3. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: A systematic review and metaanalysis. JAMA. 1997;277:739-745,
4. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413-2446
5. Chalmers J, Zanchetti A. The 1996 report of a World Hearth Organization expert committee on hypertension control. J Hypertens. 1996;14:929-933.
6. Collins R, Peto R, Godwin J, MacMahon S. Blood pressure and coronary heart disease. Lancet. 1990;336:370-371.
7. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. Protocol for prospective collaborative overviews of major randomized trials of blood pressure lowering treatments. J Hypertens. 1998;16:127-137.
8. . SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older per-, sons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
9. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350:757-764.
10. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
11. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
12. Grimm RH Jr. Antihypertensive therapy: Taking lipids into consideration. Am Heart J. 1991;122:910-918.
13. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials: Blood Pressure Lowering Treatment Trialists' Collaboration: Lancet. 2000;356:1955-1964.
14. Pahor M, Psaty BM, Alderman MH, et al. Health outcomes associated with h calcium antagonists compared with other first-line antihypertensive theraples: A meta-analysis of randomised controlled trials. Lancet. 2000;356:1949-1954.
15. Poulter NR. Treatment of hypertension: A clinical epidemiologist's view. J Cardiovasc Pharmacol. 1991;1B(suppl 2):S35-S38.
16. Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of mild hypertension study: Final results: Treatment of Mild Hypertension Study Research Group. JAMA. 1993;270:713-724.
17. Materson BJ, Reda DJ, Cushman WC, et al. Singledrug therapy for hypertension in men: A comparison of six antihypertensive agents with placebo: The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med. 1993;328:914-921.
18. Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens. 1996;9:342-360.
19. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2000;283:1967-1975.
20. Davis BR, Cutler JA, Furberg CD, et al. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: Further analyses from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Ann Intern Med. 2002;137:313-320.
21. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial. JAMA. 2002;288:2998-3007.
22. Grimm RH Jr, Margolis KL, Papademetriou V, et al. Baseline characteristics of participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2001;37:19-27.
23. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Bood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
24. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation: Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470.
25. Levey AS, Greene T, Kusek JW, et al. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol. 2000;11:155A.
26. Piller LB, Davis BR, Cutler JA, et al. Validation of heart failure events in ALLHAT participants assigned to doxasosin. Curr Control Trials Cardiovasc Med. 2002;3:10.
27. Public Health Service-Health Care Financing Administration. International Classification of Diseases, Ninth Revision (ICD-9). 6th Ed. Bethesda, Md; US Dept of Health and Human Services; 2001. DHHS Publication No. (PHS) 80-1260.
28. Dunnett CW. A multiple comparisons procedure for comparing several treatments with a control. J Am Stat Assoc. 1955;50:1096-1121.
29. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Regression. New York, NY: Springer-Verlag; 1997.
30. Davis BR, Hardy RJ. Upper bounds for type I and II error rates in conditional power calculations. Commun Stat. 1990;19:3571-3584.
31. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70:659-663.
32. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity: The Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354:1751-1756.
33. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to doubleblind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356:366-372.
34. MacMahon S, Neal B. Differences between bloodpressure-lowering drugs. Lancet. 2000;356:352-353.
35. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypettensive drug treatment in older persons with isolated systolic hypertension: SHEP Cooperative Research Group. JAMA. 1997;27B:212-216.
36. Ad Hoc Subcommittee ofthe Liaison Committee of the World Health Organisation and the International Society of Hypertension. Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. J Hypertens. 1997;15:105-115.
37. Furberg CD, Psaty BM, Meyer JV. Nifedipine: Doserelated increase in mortality in patients with coronary heart disease. Circulation. 1995;92:1326-1331.
38. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipibne on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA. 2001;285:2719-2728.
39. Hall WD, Kusek JW, Kirk KA, et al. Short-term effects of blood pressure control and antihypertensive drug regimen on glomerular filtration rate: The African-American Study of Kidney Disease and Hypertension Pilot Study. Am J Kidney Dis. 1997;29:720-728.
40. ter Wee PM, De Micheli AG, Epstein M. Effects of calcium antagonists on renal hemodynamics and progression of nondiabetic chronic renal disease. Arch Intern Med. 1994;154:1185-1202.
41. Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 1994;90:2056-2069.
42. Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: A specific target for hypertension management. Am J Hypertens. 1999;12:205S-213S.
43. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: A meta-analysis of patientlevel data. Ann Intern Med. 2001;135:73-87.
44. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions: The SOLVD investigators. N EngI J Med. 1992;327:685-691.
45. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease: Part 2, shortterm reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-838.
46. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease: Part 1, prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774.
47. Staessen JA, Byttebier G, Buntinx F, et al. Antihypertensive treatment based on conventional or ambulatory blood pressure measurement: A randomized controlled trial: Ambulatory Blood Pressure Monitoring and Treatment of Hypertension investigators. JAMA. 1997;27B:1065-1072.
48. Franklin SS. Cardiovascular risks related to increased diastolic, systolic and pulse pressure: An epidemiologist's point of view. Pathol Biol (Paris). 1999; 47:594-603.
49. Saunders E, Weir MR, Kong BW, et al. A com parison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med. 1990;150:1707-1713.
50. Rahman M, Douglas JG, Wright JT. Pathophysiology and treatment implications of hypertension in the African-American population. Endocrinol Metab Clin North Am. 1997;26:125-144.
51. Cushman WC, Reda DJ, Perry HM, et al. Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Arch Intern Med. 2000;160:825-831.
52. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med. 2001;344:1351-1357.
53. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: Analysis of the vasodilator-heart failure trials: Vasodilator-Heart Failure Trial Study Group. J Card Fail. 1999;5:178-187.
54. Dries DL, Strong MH, Cooper RS, Drazner MH. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. J Am Coll Cardiol. 2002;40;311-317
55. Manolio TA, Cutler JA, Furberg CD, et al. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med. 1995;155:829-837.